Skip to headlines
clockwire Search
LIVE
Trump weighs strikes on Iran as Israel warns of chemical weapons Google brings back App Lock for Pixel, with a wide release set for Q1 2027 Japan coach Hajime Moriyasu leaves role with mixed legacy after lack of trophies How a little-known Beijing AI safety group became an adviser to China’s tech giants Soldiers are not above the law Some get Xi hugs and dancing children, this leader took an airport bus Why the industry is silent, and why the rupee is not expected to be devalued in the near future Beyond the Spectacle: The Technology Shaping Nigeria’s Live Experiences Wealthy Perth schools’ U-turn on $300k foreshore promise Wealthy Perth schools’ U-turn on $300k foreshore promise Anand Mahindra ‘can’t dream up a better testimonial’ for Scorpio pickup 4x4: Check who it comes from Xi-Trump-Putin summit likely to be more symbolic WATCH: Diokno questions defense witness’ qualifications Almost 300 escalators across North-South, East-West, North East Lines to be refurbished from Dec 17 Insta Stories can now be edited without deleting
‹ Back to your news
Amplia gets nod for new cancer drug trial ahead of US push

SCI & TECH United States

Amplia gets nod for new cancer drug trial ahead of US push

Covered by 2 sources · 1 wire story + 0 independent reports First reported

How each outlet tells it

Wire story · carried by The Sydney Morning Herald, The Age

Amplia gets nod for new cancer drug trial ahead of US push

Amplia gets nod for new cancer drug trial ahead of US push

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Carried by 2 outlets in 1 country

  1. The Sydney Morning Herald (AU) ·
  2. The Age (AU) ·